Manufacture and performance evaluation of a stable amorphous complex of an acidic drug molecule and Neusilin

Journal of Pharmaceutical Sciences

Volumn 100, Issue 8, 2011, Pages 3332-3344

  Maclean, Jenifer ^a   Medina, Cesar ^a   Daurio, Dominick ^a   Alvarez Nunez, Fernando ^a   Jona, Janan ^a   Munson, Eric ^b   Nagapudi, Karthik ^a  

^a AMGEN INC   (United States)

^b University of Kentucky   (United States)

Author keywords

Amorphous; Extrusion; Milling; Neusilin; Solid state NMR

Indexed keywords

ATTAPULGITE; HYDROXYPROPYLMETHYLCELLULOSE; MICROCRYSTALLINE CELLULOSE; NEUSILIN US2; STARCH; STEARIC ACID; SULINDAC; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL REACTION; DIFFERENTIAL SCANNING CALORIMETRY; DISSOLUTION; DRUG STABILITY; DRUG STRUCTURE; HUMIDITY; NUCLEAR MAGNETIC RESONANCE; PARTICLE SIZE; TABLET COMPRESSION; THERMOGRAVIMETRY; X RAY POWDER DIFFRACTION;

EID: 79958831448     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22583     Document Type: Article

References (31)

1. Kennedy M, Hu J, Gao P, Li L, Ali-Reynolds A, Chal B, Gupta V, Ma C, Mahajan N, Akrami A, Surapaneni S. 2008. Enhanced bioavailability of a poorly soluble VR1 antagonist using an amorphous solid dispersion approach: A case study. Mol Pharm 5(6):981-993.
2. Yu L. 2001. Amorphous pharmaceutical solids: Preparation, characterization and stabilization. Adv Drug Delivery Rev 48(1):27-42.
3. Serajuddin ATM. 1999. Solid dispersion of poorly water-soluble drugs: Early promises, subsequent problems, and recent breakthroughs. J Pharm Sci 88(10):1058-1066.
4. Guo Y, Byrn SR, Zografi G. 2000. Physical characteristics and chemical degradation of amorphous quinapril hydrochloride. J Pharm Sci 89(1):128-143.
5. Miyazaki T, Yoshioka S, Aso Y, Kojima S. 2004. Ability of polyvinylpyrrolidone and polyacrylic acid to inhibit the crystallization of amorphous acetaminophen. J Pharm Sci 93(11):2710-2717.
6. Janssens S, de Armas HN, D'Autry W, Van Schepdael A, Van Den Mooter G. 2008. Characterization of ternary solid dispersions of Itraconazole in polyethylene glycol 6000/polyvidone-vinylacetate 64 blends. Eur J Pharm Biopharm 69(3):1114-1120.
7. Konno H, Handa T, Alonzo DE, Taylor LS. 2008. Effect of polymer type on the dissolution profile of amorphous solid dispersions containing felodipine. Eur J Pharm Biopharm 70(2):493-499.
8. Janssens S, De Zeure A, Paudel A, Van Humbeeck J, Rombaut P, Van Den Mooter G. Influence of preparation methods on solid state supersaturation of amorphous solid dispersions: A case study with Itraconazole and Eudragit E100. Pharm Res 27(5):775-785.
9. Rumondor ACF, Marsac PJ, Stanford LA, Taylor LS. 2009. Phase behavior of poly(vinylpyrrolidone) containing amorphous solid dispersions in the presence of moisture. Mol Pharm 6(5):1492-1505.
10. Law D, Schmitt EA, Marsh KC, Everitt EA, Wang W, Fort JJ, Krill SL, Qiu Y. 2004. Ritonavir-PEG 8000 amorphous solid dispersions: In vitro and in vivo evaluations. J Pharm Sci 93(3):563-570.
11. Gupta MK, Vanwert A, Bogner RH. 2003. Formation of physically stable amorphous drugs by milling with neusilin. J Pharm Sci 92(3):536-551.
12. Bahl D, Bogner RH. 2006. Amorphization of indomethacin by co-grinding with Neusilin US2: Amorphization kinetics, physical stability and mechanism. Pharm Res 23(10):2317-2325.
13. Watanabe T, Wakiyama N, Usui F, Ikeda M, Isobe T, Senna M. 2001. Stability of amorphous indomethacin compounded with silica. Int J Pharm 226(1-2):81-91.
14. Watanabe T, Hasegawa S, Wakiyama N, Kusai A, Senna M. 2002. Prediction of apparent equilibrium solubility of indomethacin compounded with silica by 13C solid state NMR. Int J Pharm 248(1-2):123-129.
15. Kinoshita M, Baba K, Nagayasu A, Yamabe K, Shimooka T, Takeichi YI, Azuma M, Houchi H, Minakuchi K. 2002. Improvement of solubility and oral bioavailability of a poorly water-soluble drug, TAS-301, by its melt-adsorption on a porous calcium silicate. J Pharm Sci 91(2):362-370.
16. Mallick S, Pattnaik S, Swain K, De PK, Saha A, Ghoshal G, Mondal A. 2008. Formation of physically stable amorphous phase of ibuprofen by solid state milling with kaolin. Eur J Pharm Biopharm 68(2):346-351.
17. Tros deIlarduya MC, Martin C, Goni MM, Martinez-Oharriz MC. 1997. Polymorphism of Sulindac: Isolation and characterization of a new polymorph and three new solvates. J Pharm Sci 86(2):248-251.
18. Descamps M, Willart JF, Desprez S. 2005. Transformation of pharmaceutical compounds by mechanical activation. Solid-Solid Phase Transformations in Inorganic Materials, Proceeding of the International Conference. Phoenix, Arizona 1:835-841.
19. Descamps M, Willart JF, Dudognon E, Caron V. 2007. Transformation of pharmaceutical compounds upon milling and comilling: The role of Tg. J Pharm Sci 96(5):1398-1407.
20. Crowley KJ, Zografi G. 2002. Cryogenic grinding of indomethacin polymorphs and solvates: Assessment of amorphous phase formation and amorphous phase physical stability. J Pharm Sci 91(2):492-507.
21. Otsuka M, Matsumoto T, Kaneniwa N. 1986. Effect of environmental temperature on polymorphic solid-state transformation of indomethacin during grinding. Chem Pharm Bull 34(4):1784-1793.
22. Douglas AW. 1978. Carbon-13 nuclear magnetic resonance studies of (Z)-5-fluoro-2-methyl-1-{[p-(methylsulfinyl)phenyl]methylene}-1H-indene-3-acetic acid (sulindac) and some related compounds. Can J Chem 56(16):2129-2133.
23. Watanabe T, Hasegawa S, Wakiyama N, Usui F, Kusai A, Isobe T, Senna M. 2002. Solid state radical recombination and charge transfer across the boundary between indomethacin and silica under mechanical stress. J Solid State Chem 164(1):27-33.
24. Vadher Ambarish H, Parikh Jolly R, Parikh Rajesh H, Solanki Ajay B. 2009. Preparation and characterization of co-grinded mixtures of aceclofenac and neusilin US2 for dissolution enhancement of aceclofenac. AAPS Pharm Sci Tech 10(2):606-614.
25. Bahl D, Bogner Robin H. 2008. Amorphization alone does not account for the enhancement of solubility of drug co-ground with silicate: The case of indomethacin. AAPS Pharm Sci Tech 9(1):146-153.
26. Llinas A, Box KJ, Burley JC, Glen RC, Goodman JM. 2007. A new method for the reproducible generation of polymorphs: Two forms of sulindac with very different solubilities. J Appl Crystallogr 40(2):379-381.
27. Gao P, Akrami A, Alvarez F, Hu J, Li L, Ma C, Surapaneni S. 2009. Characterization and optimization of AMG 517 supersaturatable self-emulsifying drug delivery system (S-SEDDS) for improved oral absorption. J Pharm Sci 98(2):516-528.
28. Gao P, Guyton ME, Huang T, Bauer JM, Stefanski KJ, Lu Q. 2004. Enhanced oral bioavailability of a poorly water soluble drug PNU-91325 by supersaturatable formulations. Drug Dev Ind Pharm 30(2):221-229.
29. Gao P, Rush BD, Pfund WP, Huang T, Bauer JM, Morozowich W, Kuo M-S, Hageman MJ. 2003. Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability. J Pharm Sci 92(12):2386-2398.
30. Sinswat P, Matteucci ME, Johnston KP, Williams RO, III. 2007. Dissolution rates and supersaturation behavior of amorphous repaglinide particles produced by controlled precipitation. J Biomed Nanotechnol 3(1):18-27.
31. Nagapudi K, Jona J. 2008. Amorphous active pharmaceutical ingredients in preclinical studies: Preparation, characterization, and formulation. Curr Bioact Compd 4(4):213-224.